

Claim 2 (amended):

The method, according to claim 1, which comprises intracerebral transplantation of said stem cell into a damaged brain.

Claim 3 (amended):

The method, according to claim 1, wherein the treatment is for a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Korsakoff's disease and Creutzfeld-Jacob disease.

Claim 4 (amended):

The method, according to claim 1, wherein said haematopoietic stem cell is conditionally immortal.

Claim 5 (amended):

The method, according to claim 4, wherein said cell comprises a temperature sensitive oncogene which is not expressed at a temperature above 35 C.

Claim 6 (amended):

The method, according to claim 5, wherein said onocogene expresses the SV40 T-antigen.

**BEST AVAILABLE COPY**

Claim 7 (amended):

A<sup>2</sup>

The method, according to claim 1, wherein said haematopoietic stem cell is genetically transformed to express a therapeutic heterologous gene product.

---

Please cancel claims 8 and 9 and add the following new claims:

---

10. A pharmaceutical composition for treating a sensory, motor and/or cognitive deficit, wherein said composition comprises a haematopoietic stem cell and a pharmaceutically acceptable carrier.

A<sup>3</sup>

11. The composition, according to claim 10, wherein said haematopoietic stem cell is conditionally immortal.

12. The composition, according to claim 11, wherein the cell comprises a temperature sensitive oncogene which is not expressed at a temperature above 35°C.

13. The composition, according to claim 12, wherein the oncogene expresses SV40 T-antigen.

14. The composition, according to claim 10, wherein the haematopoietic stem cell is genetically transformed to express a therapeutic heterologous gene product.

---